Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Engineering an affibody-functionalized hydrogel for the controlled release of insulin-like growth factor 1 (IGF-1)

FY 2022-23

Summary
Insulin-like growth factor 1 (IGF-1) is a pleiotropic hormone that has been implicated in promoting cell proliferation and mediating inflammation within the central nervous system. Accordingly, IGF-1 has applications as a potential peptide therapeutic for the treatment of human diseases such as retinal degeneration. Despite its therapeutic potential, IGF-1 faces challenges in delivery due to its physical properties and inherent instability, leading to poor pharmacokinetics and tissue penetration. To overcome this challenge, the Shoichet laboratory has developed a biocompatible hydrogel functionalized with an engineered IGF-1-binding affibody to sustain the release of IGF-1. Despite these advances, the chemistries used yielded a low degree of hydrogel functionalization. The proposed research aims to develop an affibody-based controlled release system for IGF-1 with improved functionalization of the hydrogel polymer and tuned IGF-1 affibody affinity to increase the duration over which therapeutic levels of bioactive IGF-1 can be stably released. Two independent functionalization strategies for immobilizing IGF-1-binding affibody onto a hyaluronan-ketone (HAK) hydrogel will be evaluated. Subsequently, release assays followed by ELISA will be used to measure the amount of IGF-1 released from HAK over time. Bioactivity of released IGF-1 will be determined using MCF-7 cells, which express the IGF-1 receptor. Molecular modelling will elucidate the amino acids that are critical for the interaction between the IGF-1-binding affibody and IGF-1, and mutational analysis will be performed to derive variants with different affinities. The research outlined in this proposal seeks to overcome the challenges associated with stable and sustained delivery of bioactive IGF-1.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
485903
Name
Lu Sophia P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineering an affibody-functionalized hydrogel for the controlled release of insulin-like growth factor 1 (IGF-1)
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Affibody; Biologics; Biomaterials; Controlled Release; Hydrogel; Protein Engineering
Abstract
Insulin-like growth factor 1 (IGF-1) is a pleiotropic hormone that has been implicated in promoting cell proliferation and mediating inflammation within the central nervous system. Accordingly, IGF-1 has applications as a potential peptide therapeutic for the treatment of human diseases such as retinal degeneration. Despite its therapeutic potential, IGF-1 faces challenges in delivery due to its physical properties and inherent instability, leading to poor pharmacokinetics and tissue penetration. To overcome this challenge, the Shoichet laboratory has developed a biocompatible hydrogel functionalized with an engineered IGF-1-binding affibody to sustain the release of IGF-1. Despite these advances, the chemistries used yielded a low degree of hydrogel functionalization. The proposed research aims to develop an affibody-based controlled release system for IGF-1 with improved functionalization of the hydrogel polymer and tuned IGF-1 affibody affinity to increase the duration over which therapeutic levels of bioactive IGF-1 can be stably released. Two independent functionalization strategies for immobilizing IGF-1-binding affibody onto a hyaluronan-ketone (HAK) hydrogel will be evaluated. Subsequently, release assays followed by ELISA will be used to measure the amount of IGF-1 released from HAK over time. Bioactivity of released IGF-1 will be determined using MCF-7 cells, which express the IGF-1 receptor. Molecular modelling will elucidate the amino acids that are critical for the interaction between the IGF-1-binding affibody and IGF-1, and mutational analysis will be performed to derive variants with different affinities. The research outlined in this proposal seeks to overcome the challenges associated with stable and sustained delivery of bioactive IGF-1.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lu, Sophia P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~